Quarterly report · Q1
4671.TEDINET S100RP4T
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥10.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.6bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥249m | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥681m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥303m | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥769m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥292m | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥748m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥124m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥124m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥37.1bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥38.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥38.2bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.2bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥12.3bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥26.0bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥23.6bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.6bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥11.07 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥42.32 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥11.05 | 2023-04-01 → 2023-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.25 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 69.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 61.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | ¥0 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥145m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥6.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥348m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥55m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥190m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥190m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥8m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥10.6bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥10.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥0 |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | ¥395m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥108m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.6bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥855m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥102m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥102m |
| jpcrp040300-q1r_E04982-000ICT Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | −¥73m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥789m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 358
| Item | Context | Value | Unit |
|---|---|---|---|
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |